HPV Vaccination for a 37-Year-Old with HPV Type 13
Yes, this 37-year-old patient can and should receive the 9-valent HPV vaccine (Gardasil 9) using a 3-dose schedule at 0,2, and 6 months, as the vaccine is FDA-approved through age 45 and will provide protection against the nine vaccine-targeted HPV types regardless of existing HPV 13 infection.
Key Clinical Context
HPV type 13 is not one of the nine types covered by Gardasil 9 (which targets types 6,11,16,18,31,33,45,52, and 58). This is actually advantageous—the patient can receive full benefit from vaccination against all nine vaccine types since they are not infected with any of them 1.
Regulatory Approval and Age Eligibility
The FDA expanded Gardasil 9 approval to ages 9-45 years in both women and men in 2018 2. The patient at age 37 falls well within the approved age range 1.
Dosing Schedule
Administer three 0.5 mL intramuscular doses at 0,2, and 6 months 1. This is the only FDA-approved schedule for adults; the 2-dose schedule is reserved exclusively for those who initiate vaccination between ages 9-14 years 1.
Minimum Acceptable Intervals (if schedule disruption occurs):
- Minimum 4 weeks between doses 1 and 2
- Minimum 12 weeks between doses 2 and 3
- Minimum 24 weeks between doses 1 and 3 3, 1
Clinical Rationale for Vaccination at Age 37
While ACIP's 2019 guidance describes vaccination for ages 27-45 as "shared clinical decision-making" rather than routine recommendation 2, several factors support vaccination in this case:
Protection against future HPV exposure: Most sexually active adults have been exposed to some HPV types, but new infections can occur with new sexual partners 2. The patient is unlikely to have been infected with all nine vaccine types 4.
Cancer prevention benefit: The nine vaccine types are responsible for approximately 84% of HPV-related anogenital cancers and 90% of high-risk precancerous cervical lesions 5. Even partial protection provides meaningful cancer risk reduction.
Existing HPV infection does not contraindicate vaccination: The vaccine does not alter outcomes of established infections but prevents new infections with other vaccine types 4, 3.
Important Caveats
The vaccine will NOT treat or clear the existing HPV 13 infection 4. HPV 13 is typically associated with oral focal epithelial hyperplasia (Heck's disease), not the anogenital or oropharyngeal cancers targeted by vaccination.
Cervical cancer screening must continue unchanged regardless of vaccination status, as the vaccine does not protect against all oncogenic HPV types 4, 3, 6.
Contraindication: Do not administer if the patient has a history of immediate hypersensitivity to yeast or any vaccine component 4, 1.
Administration Considerations
- Inject intramuscularly in the deltoid region 1
- Observe for 15 minutes post-injection due to syncope risk 4, 1
- Can be given simultaneously with other age-appropriate vaccines at different anatomic sites 3, 1
- Most common adverse events are injection-site reactions (pain, swelling) and headache 7, 1
Evidence Quality Note
The evidence supporting vaccination through age 45 comes from bridging immunogenicity and safety data, as clinical efficacy trials in this age group measured surrogate endpoints rather than cancer outcomes 2. However, the FDA approval and demonstrated immunogenicity support the intervention's benefit-risk profile 1.